Rgenta Therapeutics Unveils Preclinical Data on RGT-61159
WOBURN, Mass. – Rgenta Therapeutics, a pioneering biotechnology firm focused on the development of small molecule drugs targeting RNA for cancer and neurological disorders, has made an exciting announcement regarding its lead program, RGT-61159. This promising small molecule inhibitor, which selectively targets MYB RNA, will have its preclinical findings showcased at the esteemed European Hematology Association (EHA) 2025 Congress. The event is set to take place in June, where professionals in the hematology field will gather to discuss advancements and research.
Details of the Upcoming Presentation
The presentation will highlight the significant anti-tumor effects of RGT-61159 in various leukemia disease models that carry common genetic abnormalities associated with acute myeloid leukemia (AML). Leading the session is Patricia Soulard, who will present the findings during Poster Session 2 on June 14, 2025, from 18:30 to 19:30 CEST. The abstract for the presentation is denoted as PS1424, and attendees can look forward to learning more about the therapeutic potential of RGT-61159.
Understanding RGT-61159's Mechanism
The small molecule RGT-61159 has been ingeniously designed to modulate splicing of the MYB transcription factor. This alteration effectively inhibits the oncogenic MYB protein, which is known to play a crucial role in the survival and proliferation of cancer cells that express it in high volumes. MYB is recognized for its role as a master regulator in cell processes such as proliferation, self-renewal, and differentiation. Abnormal MYB expression has been implicated in numerous cancers, including adenoid cystic carcinoma (ACC), AML, T-cell acute lymphoblastic leukemia (T-ALL), colorectal cancer (CRC), small cell lung cancer (SCLC), and breast cancer.
Ongoing Clinical Studies
Rgenta Therapeutics is actively evaluating RGT-61159 in a pivotal multi-center, open-label Phase 1a/b clinical study. This trial targets patients diagnosed with advanced relapsed or refractory ACC or CRC, aiming to assess the safety, tolerability, pharmacokinetics, and efficacy of the treatment. The study is designed to advance understanding of how RGT-61159 engages its target and affects clinical outcomes in these patient populations.
About Rgenta Therapeutics
Founded on a commitment to innovate, Rgenta Therapeutics develops a cutting-edge pipeline of oral RNA-targeting small molecule therapies, primarily focusing on oncology and neurological disorders. The company’s proprietary technology leverages extensive genomic data to pinpoint RNA processing events that can be targeted therapeutically. Their approach aims to unlock the potential of drugging previously inaccessible targets in the realm of human diseases, fulfilling an essential need in the treatment landscape.
Contact Information
For more inquiries, interested parties can reach out through Wheelhouse Life Science Advisors. Investors can contact Sylvia Wheeler, while media inquiries should be directed to Aljanae Reynolds. Both are well-positioned to provide further information about Rgenta Therapeutics and its initiatives.
Frequently Asked Questions
What is RGT-61159?
RGT-61159 is a small molecule inhibitor targeting MYB RNA, which plays a key role in cell proliferation and cancer progression.
Where will the data on RGT-61159 be presented?
The preclinical data will be presented at the European Hematology Association (EHA) 2025 Congress.
What types of cancer is RGT-61159 being studied for?
RGT-61159 is being evaluated for its effects on several types of cancer, including acute myeloid leukemia and colorectal cancer.
What is the focus of Rgenta Therapeutics?
Rgenta Therapeutics focuses on developing oral small molecule medications targeting RNA to treat oncology and neurological disorders.
How can I find out more about the clinical trials?
Additional information can be found by checking ClinicalTrials.gov for ongoing study details.
